| Ytd | -49.13% | |
| 1y | -72.24% |
| Open | 2.35 | Prev Close | 2.31 | Low | 2.33 | High | 2.37 | Mkt Cap | 6.74M |
| Vol | 7.30K | Avg Vol | 52.45K | EPS | -7.48 | P/E | N/A | Forward P/E | -0.24 |
| Beta | 0.40 | Short Ratio | 0.77 | Inst. Own | 3.57% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 2.46 | 200-d Avg | 3.12 | 1yr Est | 1.30 |
PR Audio: BROOMFIELD, Colo., October 8, 2026 – PRISM MediaWire (Press Release Service – Press Releas
New criteria fully approved at nine of eleven active sites expected to significantly accelerate enro
PR Audio: BROOMFIELD, Colo., September 29, 2026 – PRISM MediaWire (Press Release Service – Press Rel
NYU Langone Health is a nationally recognized academic medical center with deep expertise in spine s
Aclarion, Inc. (NASDAQ: ACON - Get Free Report) was the target of a significant increase in short in
Gainers Profusa (NASDAQ:PFSA) stock increased by 112.5% to $4.36 during Thursday's pre-market s
Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 90.6% to $3.87 during Wednesday's after
OptimizeRx (NASDAQ: OPRX - Get Free Report) and Aclarion (NASDAQ: ACON - Get Free Report) are both s
Gainers Tempest Therapeutics (NASDAQ:TPST) stock increased by 41.6% to $1.07 during Tuesday's a
PR Audio: BROOMFIELD, Colo., August 20, 2026 – PRISM MediaWire (Press Release Service – Press Releas
University of Arizona College of Medicine – Phoenix is home to a leading neurosurgery and orthopedic
University of Arizona College of Medicine – Phoenix is home to a leading neurosurgery and orthopedic
Patent protects the precision of MRS data capture within the target disc — a critical step in the No
BROOMFIELD, Colo., August 12, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribu
Patent protects the precision of MRS data capture within the target disc — a critical step in the No
Aclarion, Inc. (ACON) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus E
PR Audio: BROOMFIELD, Colo., August 04, 2026 – PRISM MediaWire (Press Release Service – Press Releas
Partnership brings Nociscan for chronic low back pain to one of the nation's leading neurosurgery an
PR Audio: Broomfield, CO, July 29, 2026 – PRISM MediaWire (Press Release Service – Press Release Dis
141% year-over-year scan volume growth in first half of 2026 Reimbursement momentum in the U.K. tran
PR Audio: BROOMFIELD, Colo., July 21, 2026 – PRISM MediaWire (Press Release Service – Press Release
Abstracts presented at American Society of Pain & Neuroscience (ASPN) annual meeting across surgical
Texas Spine Care Center is a high-volume orthopedic spine practice with a philosophy of understandin
PR Audio: BROOMFIELD, Colo., July 07, 2026 – PRISM MediaWire (Press Release Service – Press Release
Texas Spine Care Center is a high-volume orthopedic spine practice with a philosophy of understandin
BROOMFIELD, Colo., June 10, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (
Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion's AI-driv
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-st
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-st
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a commercial-s
Top Wall Street analysts changed outlook on top names. For full changes, see analyst ratings page. S
Ascendiant Capital analyst Lucas Ward maintains Aclarion (NASDAQ:ACON) with a Buy and raises the
Offers $4.00 per share in cash plus CVRStock currently trades below the value of its cash and other
Aclarion (NASDAQ:ACON) reported quarterly losses of $(1.34) per share which beat the analyst consens
Lanman Spinal Neurosurgery is a leading spine-focused private practice recognized for its expertise
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-st
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-st
Patent covers use of AI in workflows of future products to accelerate company's ability to scale
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-st
Ascendiant Capital analyst Lucas Ward maintains Aclarion (NASDAQ:ACON) with a Buy and lowers the
Aclarion, Inc. (NASDAQ:ACON, ACONW))) ("Aclarion" or the "Company") today announced
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a commercial-s
Expands availability of Nociscan in the greater Los Angeles areaReinforces Nociscan's non-invasi
Aclarion, Inc. (NASDAQ: ACON) closed a $10.4 million financing at $5.18/share, boosting balance shee
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-st